Delhi HC restrains generic pharma firms from making, selling patent drug of Novartis
The plea said the plaintiff through a press release of January 28, 2019 issued by the defendant came to know about its act in launching a pharmaceutical composition comprising of the patented combination of Sacubitril and Valsartan tablet under the brand VALSAC as a combination drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 2, 2021 Category: Pharmaceuticals Source Type: news
ACC 2021 Highlights: Drugs and Alcohol ACC 2021 Highlights: Drugs and Alcohol
Aspirin dosing, alcohol and atrial fibrillation, dual vs mono antiplatelet therapy post PCI, and sacubitril/valsartan post MI are among the drug highlights from ACC 2021.theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 15, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
LIFE: ARNI Does Not Best Valsartan in Advanced Heart Failure LIFE: ARNI Does Not Best Valsartan in Advanced Heart Failure
' We were surprised and disappointed and stared at the data for a long time, partly in disbelief, ' said the lead investigator. However, a lot more is now known about this ' remarkable class of drugs. 'Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - June 8, 2021 Category: Primary Care Tags: Cardiology News Source Type: news
Sacubitril/Valsartan: Trending Toward PARADISE Post MI? Sacubitril/Valsartan: Trending Toward PARADISE Post MI?
PARADISE-MI fell short on statistical significance but investigator Marc Pfeffer is persuaded by trends for clinical benefit. The key: ' Start the drug early and sustain it, ' he tells Ileana Pina.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 19, 2021 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
Sacubitril/valsartan not superior to valsartan for advanced heart failure
(American College of Cardiology) Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - May 17, 2021 Category: International Medicine & Public Health Source Type: news
PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan PARADISE-MI Makes Me Question the Benefits of Sacubitril/Valsartan
Sacubitril valsartan (Entresto), deemed ' the Big E ' by some clinicians, has fallen short in 2 of 3 clinical trials. The latest, presented at the ACC 2021 scientific session, is PARADISE-MI.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
PARADISE-MI: Sacubitril/Valsartan Can ’t Beat Ramipril in Acute MI PARADISE-MI: Sacubitril/Valsartan Can ’t Beat Ramipril in Acute MI
Sacubitril/valsartan came suggestively close to showing efficacy for preventing cardiovascular death or heart failure events in patients with acute MI but no history of heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 16, 2021 Category: Consumer Health News Tags: Cardiology News Source Type: news
Navigating Prior Authorization and Costs for HFrEF Drugs Navigating Prior Authorization and Costs for HFrEF Drugs
Online tools and decision aids can help clinicians and patients work through the barriers that have slowed the use of new drugs such as sacubitril-valsartan.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 11, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Feb 19 2021 This Week in Cardiology Feb 19 2021 This Week in Cardiology
Bernard Lown, Type 2 MI, Sacubitril/Valsartan and COVID19 anticoagulation are discussed in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 19, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news
FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF FDA Expands Sacubitril/Valsartan Indication to Embrace Some HFpEF
The newly approved labeling for sacubitril/valsartan (Entresto) is simply for"chronic heart failure" but almost teasingly adds,"the benefits are most clearly evident" at below-normal LVEF.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - February 17, 2021 Category: Cardiology Tags: Cardiology News Alert Source Type: news
Entresto Granted Expanded Indication in Chronic Heart Failure by FDA
EAST HANOVER, N.J., Feb. 16, 2021 -- Novartis today announced that the US Food and Drug Administration (FDA) has approved the following expanded indication for Entresto® (sacubitril/valsartan): to reduce the risk of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 16, 2021 Category: Drugs & Pharmacology Source Type: news
Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF
The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 15, 2021 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF
The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 15, 2021 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news
Dec 18 2020 This Week in Cardiology Dec 18 2020 This Week in Cardiology
COVID, sacubitril/valsartan and spironolactone in patients with HFpEF, year-end comments are the topics discussed by John Mandrola, MD in this week ’s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 18, 2020 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news
FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan FDA Panel Supports Expanded HF Role for Sacubitril/Valsartan
The advisors overwhelmingly favored an expanded indication, which they then narrowed to what guidelines call ' mid-range LVEF. ' But there was debate about what it should be called in labeling.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 16, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
